ResMed Inc.

NYSE:RMD

Medical - Devices

Healthcare
$242.61 +0.85%

+$1.58 today

Market cap
$34.12B
Beta
0.78
P/E (TTM)
18.1
EPS (TTM)
$10.37
Dividend yield
1.28%
52W Low $180.27High $293.81

Volume 1.22M

Average 1.32M

RMD Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

ResMed Inc.NYSE: RMD

Depreciation & Amortization · Q4 FY2026 · quarter ended Jun 2026

Depreciation & amortization dips below year-ago levels

Q4 FY2026 depreciation & amortization of $55.12M fell 25.8% year over year, behind the +3.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 20.2% from the prior quarter. Over 3 fiscal years it compounded at +7.3% a year.

Context

  • Depreciation & amortization amounted to 4.3% of revenue in FY2026, down 0.3 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.8% toward the trailing-twelve-month pace of +3.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$55.12M-20.2% QoQ
Last fiscal yearJun 2026
$244.15M+3.5% YoY
LTMJun 2026
$244.15M+3.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.8%——
1 year+3.5%——
3-year CAGR+7.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2026
244.15M USD
Year-over-year change
+3.5%
4-year CAGR
+5.9%

Depreciation & Amortization vs competitors

How RMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.5% is the 7th highest of 9, against a peer median of +10.1%.
  • Depreciation & amortization amounts to 4.3% of revenue for RMD, versus a peer median of 6.8%.
RMD Competitors
Depreciation & Amortization for RMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$2.85B USD-3.4%+3.1%7.6%
BSXBoston Scientific CorporationLTM Jun 2026$1.41B USD+7.5%+6.4%6.7%
PHGKoninklijke Philips N.V.LTM Jun 2026€1.23B EUR+68.7%-11.1%7.0%
ISRGIntuitive Surgical, Inc.LTM Sep 2026$864.9M USD+48.9%+22.8%7.5%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$607M USD+7.1%-3.0%3.0%
RMDResMed Inc.LTM Jun 2026$244.15M USD+3.5%+7.3%4.3%
TFXTeleflex IncorporatedLTM Jun 2026$181.49M USD-33.6%-8.3%7.0%
INSPInspire Medical Systems, Inc.LTM Jun 2026$17.21M USD+59.5%+95.8%1.9%
ELMDElectromed, Inc.LTM Mar 2026$1.11M USD+12.8%+23.1%1.5%
Peer median (excluding RMD) —+10.1%+4.8%6.8%

Competitors are the stored peer set for RMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income779.44M897.56M1.02B1.4B1.52B
Depreciation & Amortization193.84M197.56M216.21M235.81M244.15M
Deferred Income Tax0216K000
Stock-Based Compensation65.26M71.14M80.18M91.66M104.35M
Change in Working Capital(708.08M)(462.13M)44.78M16.74M(74.24M)
Accounts Receivables19.35M(106.51M)(134.28M)(76.68M)(96.78M)
Inventory(311.68M)(248.83M)172.2M(80.17M)(9.92M)
Accounts Payables(247.63M)31.34M090.96M172.72M
Other Working Capital(168.11M)(138.13M)6.86M82.63M(140.26M)
Other Non-Cash Items20.69M(11.05M)39.13M6.66M8.28M
Operating Cash Flow351.15M693.3M1.4B1.75B1.81B
Capital Expenditures(156.04M)(134M)(114.86M)(89.87M)(156.29M)
Acquisitions (Net)(42.78M)(1.01B)(133.46M)(139.25M)(350.72M)
Purchases of Investments(20.72M)(32.23M)(22.46M)(6.42M)(28.54M)
Sales of Investments6.8M3.94M1M02.75M
Other Investing Activities(17.18M)15.2M(15.4M)35.48M(12.41M)
Investing Cash Flow(229.92M)(1.16B)(269.78M)(200.05M)(545.2M)
Debt Repayment122M665M(730M)(40M)(10M)
Common Stock Issued47.38M49.14M53.09M74.44M74.5M
Common Stock Repurchased00(150.01M)(300.03M)(700.04M)
Dividends Paid(245.34M)(258.28M)(282.32M)(310.88M)(349.66M)
Other Financing Activities(52.41M)(32.99M)(10.05M)(29.79M)(21.83M)
Financing Cash Flow(128.36M)422.87M(1.12B)(606.25M)(1.01B)
Effect of Forex Changes(14.43M)(2.15M)(1.72M)25.8M6.18M
Net Change in Cash(21.57M)(45.82M)10.47M971.09M259.78M
Free Cash Flow195.11M559.3M1.29B1.66B1.65B

ResMed Inc.

NYSE:RMD

Intrinsic Alpha fair value

Locked

Current Price

$242.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.